7 research outputs found
Effects of nizatidine on gastric acid and bicarbonate secretion
The effects of nizatidine on human gastric parietal secretion (volume and acid output) and nonparietal secretion (volume and bicarbonate concentration and secretion) were evaluated in 18 patients with duodenal ulcer. Nizatidine reduced the volume of pentagastrin-stimulated gastric secretion and gastric acid secretion. Nizatidine also decreased the volume of nonparietal secretion and bicarbonate secretion, although bicarbonate concentration remained unchanged. © 1993 Excerpta Medica, Inc. All rights reserved
Serum pepsinogens as markers of Helicobacter pylori eradication
Various methods, both invasive and noninvasive, are used to verify Helicobacter pylori eradication, with varying degrees of accuracy. The purpose of this study was to verify the relationship between H pylori eradication and serum levels of pepsinogen A (PGA) and pepsinogen C (PGC). The study involved 79 patients who tested positive for H pylori infection after histologic examination and the urease test. Patients were treated with various drug regimens for 7 to 25 days. Two months after discontinuing treatment, endoscopy was performed to verify H pylori eradication; 33 of 79 patients were found to be free of infection. Venous blood samples were taken to measure PGA and PGC levels before and after treatment. Patients in whom H pylori infection was eradicated had a significant drop in PGA and PGC levels, whereas in patients with persisting H pylori infection, there was a trend in which pepsinogen levels coincided with the quantity of bacteria detected. These preliminary data suggest that it may be possible to evaluate H pylori eradication by means of serum pepsinogen levels, sparing patients a follow-up endoscopy. © 1995
Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly?
Risk factors of slow healing were previously researched in a large sample of duodenal (DU) and gastric ulcer (GU) patients over 65 years of age; persistence of ulcer symptoms was proven the most reliable factor in predicting nonhealing ulcer, while ulcer size was of importance only for DU. We aimed to complete the analysis, with a more careful evaluation of concomitant diseases and therapies. Ranitidine 300 mg daily was given for four to eight weeks to 310 GU and 699 DU patients. Ninety-three patients dropped out of the study; 79/294 gastric ulcers and 138/635 duodenal ulcers were unhealed after four weeks. Cardiovascular, gastrointestinal, and pulmonary disorders were the most frequent concomitant diseases; NSAIDs, cardiovascular drugs, and antihypertensives were the most frequent concomitant therapies. Esophagitis was diagnosed in 15.5% of patients. Ulcer healing was the major determinant of persistence of ulcer symptoms; esophagitis emerged as an important adjunctive and independent factor. Use of hypoglycemic agents in the whole sample and smoking habit (in GU) may have also a role. With persistence of ulcer symptoms removed from the analysis, ulcer size was the most constant factor affecting ulcer healing. NSAID use, cardiovascular disorders, esophagitis (in GU), and concomitant therapy with cardiovascular drugs (in DU) also play a role. In conclusion, persistence of ulcer symptoms, the major indicator of slow ulcer healing in the elderly, is independently affected also by the presence of esophagitis. Use of hypoglycemic agents and smoking habit may also have a role in persistence of ulcer symptoms. NSAIDs, cardiovascular disorders, cardiovascular drugs, and esophagitis affect ulcer healing, for which the most constant indicators remained persistence of ulcer symptoms and ulcer size
Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly?
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register
No abstract availabl
A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial
Multi-element interventions for first-episode psychosis (FEP) are promising, but have mostly been conducted in non-epidemiologically representative samples, thereby raising the risk of underestimating the complexities involved in treating FEP in 'real-world' services
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients
Background: Hypertension management in older patients represents a challenge, particularly when hospitalized. Objective: The objective of this study is to investigate the determinants and related outcomes of antihypertensive drug prescription in a cohort of older hospitalized patients. Methods: A total of 5671 patients from REPOSI (a prospective multicentre observational register of older Italian in-patients from internal medicine or geriatric wards) were considered; 4377 (77.2%) were hypertensive. Minimum treatment (MT) for hypertension was defined according to the 2018 ESC guidelines [an angiotensin-converting-enzyme-inhibitor (ACE-I) or an angiotensin-receptor-blocker (ARB) with a calcium-channel-blocker (CCB) and/or a thiazide diuretic; if >80 years old, an ACE-I or ARB or CCB or thiazide diuretic]. Determinants of MT discontinuation at discharge were assessed. Study outcomes were any cause rehospitalization/all cause death, all-cause death, cardiovascular (CV) hospitalization/death, CV death, non-CV death, evaluated according to the presence of MT at discharge. Results: Hypertensive patients were older than normotensives, with a more impaired functional status, higher burden of comorbidity and polypharmacy. A total of 2233 patients were on MT at admission, 1766 were on MT at discharge. Discontinuation of MT was associated with the presence of comorbidities (lower odds for diabetes, higher odds for chronic kidney disease and dementia). An adjusted multivariable logistic regression analysis showed that MT for hypertension at discharge was associated with lower risk of all-cause death, all-cause death/hospitalization, CV death, CV death/hospitalization and non-CV death. Conclusions: Guidelines-suggested MT for hypertension at discharge is associated with a lower risk of adverse clinical outcomes. Nevertheless, changes in antihypertensive treatment still occur in a significant proportion of older hospitalized patients